• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Trivalent influenza vaccine effective in children under age 2

byEmilia HermannandCordelia Ross
April 21, 2014
in Infectious Disease, Pediatrics, Public Health, Uncategorized
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Trivalent influenza vaccine (TIV) was found to be 85.5% effective in children aged 6 months to 2 years.

2. TIV was more effective against influenza A than influenza B among children aged 6 months to 5 years.

Evidence Rating Level: 2 (Good)

Study Rundown: Annual influenza vaccination is the mainstay of public health efforts to reduce the burden of seasonal influenza, a significant contributor to acute respiratory infections among pediatric patients worldwide. Although national recommendations vary, vaccination of pediatric patients is viewed as a priority. The U.S. and other nations recommend trivalent influenza vaccine (TIV) for children aged 6 months and older or live-attenuated influenza vaccine (LAIV), administered via nasal spray, for children aged 2 years and older. The role of influenza vaccination in children younger than age 2 is controversial, however, due to the lack of available data on TIV effectiveness in this age category. This study evaluated TIV effectiveness in children aged 6 months to 5 years between 2008 and 2012. Results indicate that children aged 6 months to 5 years who were vaccinated with TIV were significantly less likely to present to a hospital with influenza when compared with unvaccinated children, supporting current vaccination recommendations.  This study is particularly strong because it followed patients across four influenza seasons, but is limited by low population vaccine uptake, particularly during the 2010 season.

Click to read the study published today in Pediatrics

Relevant Reading: Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study

RELATED REPORTS

Human papillomavirus (HPV) vaccination rates have increased in recent years

Human papillomavirus vaccine effective in preventing infections in the United States

Inactivated, adjuvant enterovirus 71 vaccine is safe and effective against fatal enterovirus infections in children aged 2-71 months

In-Depth [prospective cohort study]: This study evaluated TIV effectiveness in children aged 6 months to 5 years between 2008 and 2012 in Western Australia. Children presenting with an influenza-like illness to a major pediatric teaching hospital were enrolled in the study and evaluated for the presence of the influenza virus by PCR of nasopharyngeal swabs. Children testing positive for influenza were identified as cases (N=389), while children testing negative were identified as controls (N=1514). Vaccine effectiveness, adjusting for age, gender, comorbidities, and other associated factors, was calculated to be 65.8% among all participants (95% CI: 32.1 to 82.8%), and 85.5% in children under 2 years of age (95% CI: 34.7 to 96.8%). When calculated by influenza subtype, TIV effectiveness was found to be higher for influenza A (79.6%, 95% CI: 41.6 to 92.9%) than for influenza B (47.8%, 95% CI: -12.4 to 75.8%). Among partially vaccinated children (ie. those receiving only one of two recommended doses), vaccine effectiveness was found to be 81.5% (95% CI: 54.7 to 92.4%).

More from this author: Seasonal increase in primary care visits for asthma, PCR associated with limited diagnostic utility in viral URI, Lower household income associated with higher pediatric inpatient costs, EHR useful for pediatric health insurance surveillance, Commercially purchased breast milk contaminated with pathogenic bacteria

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Influenza vaccinevaccination
Previous Post

Free drug samples may alter prescription habits of dermatologists

Next Post

Home oxygen treatment for mild bronchiolitis explored

RelatedReports

Mental health parity law associated with financial protection for children
Chronic Disease

Human papillomavirus (HPV) vaccination rates have increased in recent years

June 23, 2022
Reduced doses of human papillomavirus vaccine may be effective in preventing condyloma
Public Health

Human papillomavirus vaccine effective in preventing infections in the United States

June 23, 2022
Preterm infants responsive to PCV13 vaccine
Infectious Disease

Inactivated, adjuvant enterovirus 71 vaccine is safe and effective against fatal enterovirus infections in children aged 2-71 months

May 10, 2022
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Chronic Disease

Vaccination leads to a small absolute risk for shoulder conditions

April 22, 2022
Next Post
Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]

Home oxygen treatment for mild bronchiolitis explored

Imaging biomarkers may improve prediction of aortic valve stenosis

2 Minute Medicine Rewind April 14 – April 20, 2014

Classics Series, Landmark Trials in Medicine

The ATLAS trial: Duration of adjuvant tamoxifen in ER-positive breast cancer [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency
  • Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]
  • #VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.